{
  "id": 19554139,
  "title": "Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets",
  "url": "https://urgent.news/2026/11/11/neurosterix-pulls-in-105m-for-schizophrenia-drug-taps-cobenfy-vets",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-11T21:00:55.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/neurosterix-pulls-in-105m-for-schizophrenia-drug-recruits-cobenfy-vets/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits one of the targets of Bristol Myers Squibb’s drug. The ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}